162 results on '"Musliner, Thomas A."'
Search Results
2. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia
3. Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures: Results From the Fracture Intervention Trial
4. Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia
5. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
6. Lipoprotein Lipase Cofactor Activity of a Carboxyl-Terminal Peptide of Apolipoprotein C-II
7. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
8. Efficacy and safety of ezetimibe plus atorvastatin therapy
9. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques
10. Striated Muscle Safety of Ezetimibe/ Simvastatin (Vytorin)
11. Intestinal sterol transporters and cholesterol absorption inhibition
12. Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin
13. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
14. An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
15. Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin
16. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
17. Investigating chronic headaches
18. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
19. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
20. Vertebral Fracture Prevalence Among Women Screened for the Fracture Intervention Trial and a Simple Clinical Tool to Screen for Undiagnosed Vertebral Fractures
21. Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet: A Randomized, Controlled Trial
22. Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial
23. Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density*
24. Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study
25. Effect of Simvastatin Treatment on Cardiovascular Resource Utilization in Impaired Fasting Glucose and Diabetes: Findings from the Scandinavian Simvastatin Survival Study
26. LARGER INCREASES IN BONE MINERAL DENSITY DURING ALENDRONATE THERAPY ARE ASSOCIATED WITH A LOWER RISK OF NEW VERTEBRAL FRACTURES IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
27. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study
28. Safety and Tolerability of Cholesterol Lowering With Simvastatin During 5 Years in the Scandinavian Simvastatin Survival Study
29. Safety and tolerability of cholesterol lowering with simvastatin during 5 years of the Scandinavian Simvastatin Survival Study
30. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial
31. Abetalipoproteinemia and Hypobetalipoproteinemia: Questions Still Exceed Insights
32. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
33. Abstract 19694: Reduction in Non-hemorrhagic Stroke With Ezetimibe/Simvastatin Compared With Simvastatin Alone in the IMPROVE-IT Trial
34. Abstract 16708: Increasing Age and the Benefit From Higher-intensity Lipid Lowering With Ezetimibe/Simvastatin vs. Simvastatin Alone: Results From the IMPROVE-IT Trial
35. Abstract 17862: Benefit and Safety of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes in 4416 Women in the IMPROVE-IT Trial
36. Ezetimibe Does Not Increase Fasting Glucose Levels More than Statins Alone in Non-diabetic, Hypercholesterolemic Patients
37. RISK STRATIFICATION FOR CARDIOVASCULAR EVENTS IN THE IMPROVE-IT TRIAL
38. BASELINE LDL-C AND CLINICAL OUTCOMES WITH ADDITION OF EZETIMIBE TO STATIN IN 18,144 PATIENTS POST ACS
39. Effect of Simvastatin Treatment on Hospitalizations and Cost in 4S Patients with Impaired Fasting Glucose and Diabetes Mellitus
40. [24] Nondenaturing polyacrylamide gradient gel electrophoresis
41. CHANGES IN FASTING GLUCOSE LEVELS FOLLOWING LONGER-TERM TREATMENT WITH SIMVASTATIN MONOTHERAPY AND COMBINED EZETIMIBE+SIMVASTATIN
42. Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
43. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans
44. Effects of Ezetimibe, Ezetimibe Coadministered with Statins and Statin Therapies on Fasting Glucose Changes in Patients with Hypercholesterolemia
45. Efficacy and Safety of Ezetimibe Monotherapy in 6-10 Year Old Children with Heterozygous Familial or Non-familial Hypercholesterolemia
46. EFFICACY AND SAFETY OF EZETIMIBE MONOTHERAPY IN CHILDREN SIX TO TEN YEARS OF AGE WITH HETEROZYGOUS FAMILIAL OR NON-FAMILIAL HYPERCHOLESTEROLEMIA
47. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
48. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe–statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia
49. Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin)
50. In response to ‘ezetimibe-induced hyperlipidaemia’ case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.